Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 31 (TMEM31) is a human membrane protein, also known as testicular secretory protein Li 58, with a molecular weight of about 19.8 kDa[6][8]. The TMEM31 gene encodes a predicted single-pass or multi-pass membrane protein, but its physiological function remains largely uncharacterized. Research has highlighted TMEM31 as a potential immunogenic cancer/testis antigen, particularly in melanoma, where its epitopes have been studied for their ability to elicit cytotoxic T lymphocyte responses and for possible use in peptide and DNA vaccine development[5]. There is currently insufficient evidence regarding its endogenous biological functions, established drug interactions, or clear safety concerns. TMEM31 is not part of any major protein family such as G protein-coupled receptors, ion channels, enzymes, or transporters; it is grouped under "Other" due to lack of mechanistic data. It may serve as a biomarker target for immunotherapy in certain cancers but is not broadly used in clinical practice[5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 31 (TMEM31).